CAC
Cowen and Company Portfolio holdings
AUM
$2.9B
This Quarter Return
-4.01%
1 Year Return
+104.28%
3 Year Return
+119.87%
5 Year Return
+632.2%
10 Year Return
–
AUM
$992M
AUM Growth
+$992M
(-5.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-10.42%
Top 10 Holdings %
Top 10 Hldgs %
46.63%
Holding
744
New
209
Increased
114
Reduced
123
Closed
206
Top Buys
| 1 |
Fulcrum Therapeutics
FULC
|
$81.7M |
| 2 |
Sylvamo
SLVM
|
$65.1M |
| 3 |
ARK Innovation ETF
ARKK
|
$51.4M |
| 4 |
Adicet Bio
ACET
|
$30M |
| 5 |
Relmada Therapeutics
RLMD
|
$27.4M |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
$146M |
| 2 |
IPOF
Social Capital Hedosophia Holdings Corp. VI
IPOF
|
$49.1M |
| 3 |
CCVI
Churchill Capital Corp VI
CCVI
|
$34.2M |
| 4 |
Advanced Micro Devices
AMD
|
$27.5M |
| 5 |
Celldex Therapeutics
CLDX
|
$18M |
Sector Composition
| 1 | Healthcare | 41.72% |
| 2 | Financials | 16.16% |
| 3 | Materials | 6.85% |
| 4 | Consumer Discretionary | 6.32% |
| 5 | Industrials | 4.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Fulcrum Therapeutics
FULC
$351M
| $81.7M | 7.86% | +3,453,371 | New | +$81.7M |
|
|
2
ARK Innovation ETF
ARKK
$7.45B
| $67.9M | 6.54% | 1,025,000 +775,000 | +310% | +$51.4M |
|
|
3
Sylvamo
SLVM
$1.86B
| $65.1M | 6.26% | +1,955,000 | New | +$65.1M |
|
4
Establishment Labs
ESTA
$1.2B
| $56.1M | 5.4% | 832,187 +21,500 | +3% | +$1.45M |
|
5
FTAI Aviation
FTAI
$15.8B
| $38.3M | 3.68% | 1,486,462 -402,278 | -21% | -$10.4M |
|
6
Sumitomo Mitsui Financial
SMFG
$105B
| $35.6M | 3.43% | 5,676,605 -300,000 | -5% | -$1.88M |
|
|
7
Relmada Therapeutics
RLMD
$37.2M
| $31.4M | 3.02% | 1,164,361 +1,014,587 | +677% | +$27.4M |
|
|
8
Adicet Bio
ACET
$59.9M
| $30M | 2.88% | +1,500,055 | New | +$30M |
|
9
Stoke Therapeutics
STOK
$1.08B
| $29.9M | 2.88% | 1,420,530 +1,125,105 | +381% | +$23.7M |
|
10
Rivian
RIVN
$16.5B
| $26.8M | 2.58% | +532,300 | New | +$26.8M |
|
11
PMV Pharmaceuticals
PMVP
$74.2M
| $26.3M | 2.53% | +1,261,529 | New | +$26.3M |
|
|
AVDL
12
Avadel Pharmaceuticals
AVDL
$1.43B
| $25.5M | 2.45% | 3,732,778 | – | – |
|
13
Apyx Medical
APYX
$75.3M
| $17.2M | 1.66% | 2,634,003 +732,000 | +38% | +$4.78M |
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $17.1M | 1.65% | 722,575 +719,397 | +22,637% | +$17M |
|
|
IPOF
15
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
| $17M | 1.64% | 1,685,351 -4,863,742 | -74% | -$49.1M |
|
|
SCPL
16
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
| $16.8M | 1.62% | 1,299,219 +1,298,196 | +126,901% | +$16.8M |
|
17
Rocket Pharmaceuticals
RCKT
$354M
| $15.9M | 1.53% | 1,000,000 | – | – |
|
|
HCVIU
18
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
| $14.8M | 1.43% | 1,500,000 | – | – |
|
|
PEGR
19
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
| $14.6M | 1.4% | 1,500,000 -1,500,000 | -50% | -$14.6M |
|
20
Immunic
IMUX
$80.9M
| $14.2M | 1.37% | 1,257,146 +1,001,291 | +391% | +$11.3M |
|
|
PSTH
21
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
| $14M | 1.34% | 702,000 +300,000 | +75% | +$5.97M |
|
22
Cantaloupe
CTLP
$797M
| $13.8M | 1.33% | 2,038,479 -1,864,985 | -48% | -$12.6M |
|
23
Energy Transfer Partners
ET
$60.8B
| $12.9M | 1.24% | 1,155,000 -1,081,536 | -48% | -$12.1M |
|
24
Innoviz Technologies
INVZ
$335M
| $12.2M | 1.18% | 3,383,325 +133,463 | +4% | +$483K |
|
25
Exagen
XGN
$217M
| $11.1M | 1.07% | 1,384,631 | – | – |
|